Human IGFBP-4 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB8041
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Asp22-Glu258
Accession # AAA62670
Specificity
Clonality
Host
Isotype
Endotoxin Level
Scientific Data Images for Human IGFBP-4 Antibody
IGFBP-4 Inhibition of IGF-II-dependent Cell Proliferation and Neutralization by Human IGFBP-4 Antibody.
Recombinant Human IGFBP-4 (Catalog # 804-GB) inhibits Recombinant Human IGF-II (Catalog # 292-G2) induced proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF-II (14 ng/mL) activity elicited by Recombinant Human IGFBP-4 (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IGFBP-4 Monoclonal Antibody (Catalog # MAB8041). The ND50 is typically 20-80 µg/mL.Applications for Human IGFBP-4 Antibody
Western Blot
Sample: Recombinant Human IGFBP-4 (Catalog # 804-GB)
Neutralization
Human IGFBP-4 Sandwich Immunoassay
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IGFBP-4
Human IGF binding protein 4 (IGFBP-4) was isolated from human plasma based on its ability to bind immobilized IGF-I. Human IGFBP-4 cDNA encodes a 258 amino acid (aa) residue precursor protein with a predicted 21 aa residue signal peptide that is processed to generate the 237 aa residue mature human IGFBP-4. The human IGFBP-4 contains a potential N-linked glycosylation site and shares approximately 90% amino acid sequence identity with both the mouse and rat IGFBP-4. According to the nomenclature of IGFBPs defined at the 4th International Symposium of IGFs (1997, Tokyo), six high-affinity IGF binding proteins (IGFBP-1, -2, -3, 4, -5, -6), and four IGFBP-related proteins (IGFBPr-1, - 2, -3, -4) have been identified. All IGFBPs have a high cysteine content and share conserved cysteine residues that are clustered in the amino- and carboxy-terminal third of the molecule. IGFBPs have been shown to either inhibit or enhance the biological activities of IGF, or act in an IGF-independent manner. Post-translational modification of IGFBPs, including phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins for IGF and may indirectly regulate IGF actions.
References
- Jones, J.I. and D.R. Clemons (1995) Endocrine Rev. 16:3.
- Kelly, K.M. et al. (1996) Intl. J. Biochem. Cell Biol. 28:619.
- Kim, H-S. et al. (1997) Proc. Natl. Acad. Sci. USA 94:12981.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional IGFBP-4 Products
Product Documents for Human IGFBP-4 Antibody
Product Specific Notices for Human IGFBP-4 Antibody
For research use only